Satellos Bioscience Inc. has reported results from preclinical studies in a disease model of Duchenne muscular dystrophy (DMD). The company's proprietary Myoregenx assay platform identified a protein kinase (K9) as a potential drug target to modulate polarity in muscle stem cells.